title: Lack of antilipoprotein lipase antibodies in Takayasu's arteritis.
abstract: BACKGROUND
  Antilipoprotein lipase (anti-LPL) antibodies were described in rheumatic diseases. In systemic lupus erythematosus they were highly associated with inflammatory markers and dyslipidemia, and may ultimately contribute to vascular damage. The relevance of this association in Takayasu's arteritis, which is characterized by major inflammatory process affecting vessels, has not been determined.
  
  
  OBJECTIVE
  To analyze the presence of anti-LPL antibodies in patients with Takayasu's arteritis and its association with inflammatory markers and lipoprotein risk levels. Methods. Thirty sera from patients with Takayasu's arteritis, according to ACR criteria, were consecutively included. IgG anti-LPL was detected by a standard ELISA. Lipoprotein risk levels were evaluated according to NCEP/ATPIII. Inflammatory markers included ESR and CRP values.
  
  
  RESULTS
  Takayasu's arteritis patients had a mean age of 34 years old and all were females. Half of the patients presented high ESR and 60% elevated CRP. Lipoprotein NCEP risk levels were observed in approximately half of the patients: 53% for total cholesterol, 43% for triglycerides, 16% for HDL-c and 47% for LDL-c. In spite of the high frequency of dyslipidemia and inflammatory markers in these patients no anti-LPL were detected.
  
  
  CONCLUSIONS
  The lack of anti-LPL antibodies in Takayasu's disease implies distinct mechanisms underlying dyslipidemia compared to systemic lupus erythematosus.
authors.affiliation: Disciplina de Reumatologia, Faculdade de Medicina da Universidade de São Paulo, 0124-6903 São Paulo, Brazil.
authors.forename: Jozélio Freire
authors.initials: JF
authors.lastname: de Carvalho
authors.forename: Rosa Maria Rodrigues
authors.initials: RM
authors.lastname: Pereira
authors.forename: Vilma Santos Trindade
authors.initials: VS
authors.lastname: Viana
authors.forename: Eloísa
authors.initials: E
authors.lastname: Bonfá
authors.forename: Yehuda
authors.initials: Y
authors.lastname: Shoenfeld
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood*; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D000939:Epitopes; D005260:Female; D006801:Humans; D006973:Hypertension; D007074:Immunoglobulin G / Q000097:blood*; D050356:Lipid Metabolism / Q000276:immunology; D008071:Lipoprotein Lipase / Q000276:immunology*; D011241:Prednisone / Q000627:therapeutic use; D013625:Takayasu Arteritis / Q000097:blood / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism / Q000503:physiopathology; D014280:Triglycerides / Q000097:blood
chemical_list: D015415:Biomarkers; D000939:Epitopes; D007074:Immunoglobulin G; D014280:Triglycerides; D002097:C-Reactive Protein; D002784:Cholesterol; D008071:Lipoprotein Lipase; D011241:Prednisone